McKesson (MCK)
(Delayed Data from NYSE)
$595.73 USD
+5.74 (0.97%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $595.76 +0.03 (0.01%) 7:28 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$595.73 USD
+5.74 (0.97%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $595.76 +0.03 (0.01%) 7:28 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
Edwards Lifesciences' (EW) Global Sales Robust Amid Cost Woes
by Zacks Equity Research
Edwards Lifesciences (EW) is registering robust HemoSphere sales in the United States.
Bet on These 4 Low-Beta, High-Dividend MedTech Stocks for 2022
by Riya Anand
Stocks like Becton, Dickinson and Company (BDX), Phibro Animal Health (PAHC), McKesson Corporation (MCK) and UnitedHealth Group Inc (UNH) are right picks with strong fundamentals.
Bruker's (BRKR) Buyout to Expand Mass Spectrometry Prospects
by Zacks Equity Research
Bruker's (BRKR) acquisition of IonSense will reach the DART ionization technology to a wider customer base.
Here's Why You Should Invest In Henry Schein (HSIC) Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC) owing to the favorable dental business trends.
Here's Why You Should Hold on to Chemed (CHE) Stock For Now
by Zacks Equity Research
Investors are optimistic about robust performance by Chemed's (CHE) Roto-Rooter arm.
Here's Why You Should Retain Amedisys (AMED) Stock For Now
by Zacks Equity Research
Investors are optimistic about Amedisys' (AMED) strong segmental performance and strategic buyouts.
Thermo Fisher (TMO) Debuts Raman Spectroscopic Analyzer
by Zacks Equity Research
Thermo Fisher's (TMO) Ramina Process Analyzer allows users to conduct precise in situ Raman measurements in a simple manner with high accuracy.
Walgreens (WBA) Expands Medical Care Offerings in California
by Zacks Equity Research
Walgreens' (WBA) new initiative is intended to reduce care gaps and advance care management by providing access to more affordable and convenient services.
5 Dividend Growth Stocks for Safe Income Amid Volatility
by Sweta Killa
The Kroger (KR), NVIDIA (NVDA), Jones Lang LaSalle (JLL), Paychex (PAYX) and McKesson (MCK) could be compelling picks amid market volatility.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments.
Quest Diagnostics (DGX) Inks New Diabetic Retinal Imaging Deal
by Zacks Equity Research
Quest Diagnostics' (DGX) new collaboration with IRIS will enhance access to diabetic retinopathy screening in the United States.
Bruker (BRKR) to Support Biopharma Industries With New Buyout
by Zacks Equity Research
Bruker's (BRKR) recent buyout strengthens the company as a key software and solutions provider for small molecule, biologics and new drug modalities pharma companies.
Why McKesson (MCK) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why You Should Retain Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Teleflex (TFX) on increased UroLift demand and strong vascular business.
Medtronic (MDT) Reports Positive Findings Backing RDN System
by Zacks Equity Research
Medtronic's (MDT) Symplicity Spyral RDN system demonstrated durable and clinically significant reductions in blood pressure at the SPYRAL HTN-ON MED trial.
Medtronic (MDT) Innovations Aid Global Growth, Volume Woe Stays
by Zacks Equity Research
In the neuroscience portfolio, Medtronic (/MDT) is gaining market share in Cranial and Spinal technologies.
Abbott (ABT) Aveir VR Leadless Pacemaker Receives FDA Nod
by Zacks Equity Research
Abbott's (ABT) Aveir VR is a leadless pacemaker designed to treat patients with slow heart rhythms in the United States.
Zimmer Biomet (ZBH) Hurt by China VBP, COVID-Led Staff Shortage
by Zacks Equity Research
Zimmer Biomet (ZBH) expects to face an adverse pricing impact in the first half of 2022, which is being compared to the non-VBP first half of 2021.
Here's Why You Should Retain AmerisourceBergen (ABC) Stock
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
NextGen (NXGN) Introduces New Integrated Care EHR Solution
by Zacks Equity Research
NextGen's (NXGN) newest solution lends support to comprehensive primary care and behavioral health with intellectual and developmental disabilities.
STERIS (STE) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about STERIS (STE) on impressive growth across its operating segments.
Here's Why You Should Add Bruker (BRKR) Stock to Your Kitty
by Zacks Equity Research
Bruker's (BRKR) Nano Group microelectronics and semiconductor metrology tools continue to perform well on ongoing strength in bookings and backlog.
AMN Healthcare (AMN) Stock Moves Up 12.9%: What's Driving It?
by Zacks Equity Research
Investors are optimistic about AMN Healthcare's (AMN) strong segmental performance and upbeat first-quarter guidance.
Here's Why You Should Retain CVS Health (CVS) Stock For Now
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS) owing to continued progress in its consumer-centric digital solutions.
Is Innoviva (INVA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Innoviva (INVA) and McKesson (MCK) have performed compared to their sector so far this year.